JP2019505565A5 - - Google Patents

Download PDF

Info

Publication number
JP2019505565A5
JP2019505565A5 JP2018546726A JP2018546726A JP2019505565A5 JP 2019505565 A5 JP2019505565 A5 JP 2019505565A5 JP 2018546726 A JP2018546726 A JP 2018546726A JP 2018546726 A JP2018546726 A JP 2018546726A JP 2019505565 A5 JP2019505565 A5 JP 2019505565A5
Authority
JP
Japan
Prior art keywords
tyr
leu
lys
trp
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018546726A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019505565A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2016/051168 external-priority patent/WO2017091850A1/en
Publication of JP2019505565A publication Critical patent/JP2019505565A/ja
Publication of JP2019505565A5 publication Critical patent/JP2019505565A5/ja
Pending legal-status Critical Current

Links

JP2018546726A 2015-11-30 2016-11-30 新規の抗血管新生融合ポリペプチド Pending JP2019505565A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15197019.1 2015-11-30
EP15197019 2015-11-30
PCT/AU2016/051168 WO2017091850A1 (en) 2015-11-30 2016-11-30 Novel anti-angiogenic fusion polypeptides

Publications (2)

Publication Number Publication Date
JP2019505565A JP2019505565A (ja) 2019-02-28
JP2019505565A5 true JP2019505565A5 (OSRAM) 2020-01-16

Family

ID=54754521

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018546726A Pending JP2019505565A (ja) 2015-11-30 2016-11-30 新規の抗血管新生融合ポリペプチド

Country Status (12)

Country Link
US (1) US10703810B2 (OSRAM)
EP (1) EP3383921A4 (OSRAM)
JP (1) JP2019505565A (OSRAM)
KR (1) KR20180083943A (OSRAM)
CN (1) CN108699162A (OSRAM)
AU (1) AU2016363668A1 (OSRAM)
BR (1) BR112018010887A2 (OSRAM)
CA (1) CA3004918A1 (OSRAM)
EA (1) EA035586B1 (OSRAM)
MX (1) MX2018006559A (OSRAM)
SG (2) SG11201803732PA (OSRAM)
WO (1) WO2017091850A1 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3094650A2 (en) * 2014-01-13 2016-11-23 Pieris Pharmaceuticals GmbH Multi-specific polypeptide useful for localized tumor immunomodulation
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
CN109829882B (zh) * 2018-12-18 2020-10-27 广州比格威医疗科技有限公司 一种糖尿病视网膜病变分期预测方法
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
US20240182553A1 (en) * 2021-03-25 2024-06-06 Nanjing GenScript Biotech Co., Ltd. Antibody fusion proteins and uses thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE76311T1 (de) 1986-08-19 1992-06-15 Genentech Inc Einrichtung und dispersion zum intrapulmonalen eingeben von polypeptidwuchsstoffen und zytokinen.
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンaの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
ATE299892T1 (de) 1994-05-18 2005-08-15 Nektar Therapeutics Methoden und zusammensetzungen für die trockenpuderarznei aus interferonen
DE4417598A1 (de) 1994-05-19 1995-12-14 Max Planck Gesellschaft Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen
WO1996023879A1 (en) 1995-01-30 1996-08-08 Terrapin Technologies, Inc. Glubodies - multiplicities of proteins capable of binding a variety of small molecules
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
DE19641876B4 (de) 1996-10-10 2011-09-29 Iba Gmbh Streptavidinmuteine
WO1998016873A1 (en) 1996-10-14 1998-04-23 Firm Forsat Ltd. Method for preparing dispersions of chromogenic components
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
NZ508249A (en) 1998-06-08 2003-02-28 F Use of PEG-IFN-alpha conjugates in association with ribavirin for the treatment of chronic hepatitis C
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
DE19926068C1 (de) 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
CA2440582A1 (en) 2001-03-09 2002-10-03 Dyax Corp. Serum albumin binding moieties
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
CA2464690A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of apolipoprotein d
US7691970B2 (en) 2003-08-25 2010-04-06 Pieris Ag Muteins of a bilin-binding protein with affinity for a given target
AU2003275958A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of tear lipocalin
JP2007284351A (ja) 2004-07-27 2007-11-01 Osaka Bioscience Institute アミロイド蛋白質の凝集を抑制する物質とその作用
US7892827B2 (en) 2004-11-26 2011-02-22 Pieris Ag Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
WO2006078717A2 (en) * 2005-01-19 2006-07-27 Beth Israel Deaconess Medical Center Lipocalin 2 for the treatment, prevention, and management of cancer metastasis, angiogenesis, and fibrosis
CA2622441A1 (en) 2005-09-27 2007-04-05 Amunix, Inc. Proteinaceous pharmaceuticals and uses thereof
JP5746861B2 (ja) 2007-10-19 2015-07-08 アボット・ラボラトリーズAbbott Laboratories 哺乳動物のngalに結合する抗体及びその使用
US20110076723A1 (en) * 2008-05-23 2011-03-31 Samsung Electronics Co., Ltd. Antibody-peptide fused synergibody
JP5711118B2 (ja) 2008-06-24 2015-04-30 テクニッシュ ウニヴェルジテート ミュンヘン 所与の標的に対してアフィニティーを有するhNGALおよび類縁タンパク質のムテイン
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
US8133979B2 (en) 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
WO2010111625A1 (en) * 2009-03-27 2010-09-30 Zymogenetics, Inc. Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination
RU2564125C2 (ru) 2009-12-07 2015-09-27 Пирис Аг Мутеины липокалина 2 человека (lcn2, hngal) с аффинностью для определенной мишени
TWI426920B (zh) * 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗-vegf/抗-ang-2抗體
DK2606061T3 (da) * 2010-08-16 2017-11-06 Pieris Pharmaceuticals Gmbh Bindingsproteiner til hepcidin
AU2011331232B2 (en) 2010-11-15 2015-05-07 Pieris Ag Muteins of human lipocalin 2 with affinity for Glypican-3 (GPC3)
PE20150361A1 (es) * 2012-07-13 2015-03-14 Roche Glycart Ag Anticuerpos biespecificos anti-vegf/anti-ang-2 y su utilizacion en el tratamiento de enfermedades vasculares oculares
EP3441400B1 (en) 2012-11-19 2022-07-20 Pieris Pharmaceuticals GmbH Novel specific-binding polypeptides and uses thereof
JP2016528167A (ja) * 2013-04-29 2016-09-15 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft ヒトFcRn結合改変抗体及び使用方法
EP3094650A2 (en) * 2014-01-13 2016-11-23 Pieris Pharmaceuticals GmbH Multi-specific polypeptide useful for localized tumor immunomodulation
RU2723034C2 (ru) * 2014-05-22 2020-06-08 ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ Новые полипептиды со специфическим связыванием и пути их применения
AR103477A1 (es) * 2015-01-28 2017-05-10 Lilly Co Eli Compuestos de vegfa / ang2
WO2016120307A1 (en) 2015-01-28 2016-08-04 Pieris Ag Novel proteins specific for angiogenesis
WO2016131804A1 (en) 2015-02-18 2016-08-25 Sanofi Novel proteins specific for pyoverdine and pyochelin
DK3292137T3 (da) 2015-05-04 2022-10-17 Pieris Pharmaceuticals Gmbh Proteiner specifikke for cd137
BR112017020961A2 (pt) 2015-05-18 2018-07-10 Pieris Pharmaceuticals Gmbh muteína, molécula de ácido nucleico, célula hospedeira, método de produção de uma muteína e método de ligação

Similar Documents

Publication Publication Date Title
JP2019505565A5 (OSRAM)
CN110234355B (zh) 单体人IgG1 Fc和双特异性抗体
CN115057936B (zh) 异源二聚体多特异性抗体形式
JP7496091B2 (ja) 合理的に設計された新規なタンパク質組成物
JP2018509887A5 (OSRAM)
CN105315371B (zh) 抗人il-17单克隆抗体
DK2467400T3 (en) VARIANT TIMING LOBULINES WITH IMPROVED MANUFACTURING Ease
EP2050764A1 (en) Novel polyvalent bispecific antibody format and uses thereof
KR102345999B1 (ko) Il-1 베타 결합성분
JP2018537421A5 (OSRAM)
TW201643193A (zh) 一種抗pd-1的單克隆抗體及其獲得方法
JP2020504087A (ja) 4−1bb結合タンパク質及びその使用
AU2016369307A1 (en) Multi-specific antibody molecules having specificity for TNF-alpha, IL-17A and IL-17F
KR102058381B1 (ko) 인간 l1cam에 대한 인간화 항체 및 그의 제조 방법
JP2020505919A5 (OSRAM)
JP2005528914A5 (OSRAM)
JP2019506140A5 (OSRAM)
JP2025160405A (ja) 特異的結合分子
EP3154564B1 (en) New polypeptide
KR101229006B1 (ko) 이중 특이성 항체의 제조 방법
CN111699006B (zh) Il17抗体及其应用
JP7014727B2 (ja) ポリペプチドライブラリ
Krinner et al. A highly stable polyethylene glycol-conjugated human single-chain antibody neutralizing granulocyte-macrophage colony stimulating factor at low nanomolar concentration
US20240092908A1 (en) Anti-pd-1 single-domain antibody
CN117860786B (zh) 基因修饰间充质干细胞在多种疾病中的制药用途和诊断用途